• IMV Inc (TSX:IMV) has announced that the company will present at the 2020 BIO CEO and Investor Conference next month.
  • Management team members will give the presentation on February 10th, at the Marriott Marquis Hotel in New York.
  • A live webcast and replay of the presentation will be accessible online.
  • IMV’s share price is up 0.33 per cent, with shares trading at $6.16 apiece.

Representatives from biopharmaceutical company IMV Inc (IMV) will give a presentation at the BIO CEO and Investor Conference in February. The two-day conference will take place at the Marriott Marquis Hotel in New York City.

The occasion will bring together investors, industry analysts, and senior executives from biotechnology companies. The event is a great opportunity to let investors know about the novel class of immunotherapies which IMV is currently pioneering.

The conference will take place on February 10th and 11th, with company presentations on both days. IMV’s presentation is scheduled for Monday February 10th, at 9:30am Eastern Standard Time.

A live webcast of the presentation will be made available on the investors section of IMV’s website, under Events, Webcasts, and Presentations.

A replay will also be accessible, roughly one hour after the presentation. It will continue to be available for approximately 30 days.

IMV’s share price is up 0.33 per cent, with shares trading at $6.16 apiece.

More From The Market Online

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.

Telo Genomics kick-starts clinical trial for multiple myeloma patients

Telo Genomics has kick-started its clinical trial for multiple myeloma patients after receiving the first patient sample from the trial.

Theralase donates laser therapy tech to help research Parkinson’s treatment

Theralase Technologies (TSXV:TLT) has donated some of its technology to help advance university studies into Parkinson’s Disease treatment.

BioNxt reveals results from multiple sclerosis treatment study

BioNxt Solutions (CSE:BNXT) is one step closer to having its proprietary Cladribine product available to treat multiple sclerosis.